Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARA | Q07869 | 10/20 | 0.49 |
| ▸ | PPARG | P37231 | 10/20 | 0.49 |
| ▸ | PPARD | Q03181 | 4/20 | 0.47 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.47 |
| ▸ | MAOB | P27338 | 1/20 | 0.44 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.44 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.44 |
| ▸ | CYSLTR2 | Q9NS75 | 3/20 | 0.42 |
| ▸ | CYSLTR1 | Q9Y271 | 3/20 | 0.42 |
| ▸ | ACACB | O00763 | 1/20 | 0.41 |
| ▸ | TPH1 | P17752 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7068771 | 0.88 | PPARG (0.55) | PPARAPPARGPPARDSCN9AMAOB | |
| SCHEMBL7070013 | 0.86 | PPARA (0.67) | PPARAPPARGPPARD | |
| SCHEMBL7069269 | 0.86 | PPARG (0.68) | PPARAPPARG | |
| SCHEMBL7069751 | 0.85 | SCN9A (0.45) | SCN9AALOX5APTPH1 | |
| SCHEMBL7130371 | 0.84 | PPARG (0.60) | PPARAPPARG | |
| SCHEMBL7069695 | 0.84 | PPARA (0.55) | PPARAPPARGPPARDMAOBCYSLTR2 | |
| SCHEMBL5607673 | 0.83 | PPARG (0.69) | PPARAPPARGPPARDMAOB | |
| SCHEMBL7066077 | 0.83 | MAOB (0.47) | PPARAPPARGPPARDMAOBALOX5AP | |
| SCHEMBL7068763 | 0.82 | PPARG (0.60) | PPARAPPARG | |
| SCHEMBL7067684 | 0.82 | MAOB (0.47) | PPARAPPARGPPARDMAOBALOX5AP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030212100-A1 | Quinoline derivatives and medicinal use thereof | MITSUI CHEMICALS, INC. (JP) | 2003-11-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030212100-A1 | Quinoline derivatives and medicinal use thereof | PPARG, PPARD, PPARA | PPARA 3/4885PPARG 1/4885PPARD 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.